Current Edition

Aduhelm

Biogen piles on more long-term Aduhelm data, linking biomarker to Alzheimer’s clinical benefit

Despite a disastrous commercial rollout, Biogen is still producing longer-term data for beleaguered Alzheimer’s disease therapy Aduhelm. In patients who’ve been treated with Aduhelm for …

Continue Reading →
Alzheimer

CMS’ Biogen decision could spell problems for Lilly, Roche Alzheimer’s drugs, half of surveyed neurologists say

Neurologists in the U.S. are agreeing with a new draft decision from the Centers for Medicare & Medicaid Services (CMS) that restricts reimbursement of Biogen’s …

Continue Reading →
Aduhelm

Biogen’s Aduhelm call to action backfires as CMS receives many more comments in favor of restrictive coverage: analyst

During a January Q&A call with investors, Biogen chief Michel Vounatsos pressed Aduhelm supporters to fight the Centers for Medicare & Medicaid Services’ (CMS’) restrictive …

Continue Reading →
Aduhelm (aducanumab)

Amid Aduhelm’s rocky launch, Biogen eyes large-scale layoffs

Between slow sales, safety concerns and a likely European rejection, newly minted Alzheimer’s disease drug Aduhelm has proven more of a headache than a blessing …

Continue Reading →
Aduhelm (aducanumab)

ARIA side effects surface in 40% of patients on Biogen’s Alzheimer’s drug Aduhelm

Biogen’s Alzheimer’s disease drug Aduhelm has endured a headache of a launch, largely due to lingering questions about its true clinical benefit and how the …

Continue Reading →
Aduhelm

Biogen’s Aduhelm records one patient death. Is the controversial Alzheimer’s drug to blame?

Doctors already have reservations about Biogen’s controversial Alzheimer’s disease drug, Aduhelm. Now a reported death will likely trigger more doubts around its use. One patient …

Continue Reading →
Biogen

Biogen beefs up in biosimilars—again—with FDA nod for Samsung-partnered Lucentis copycat

Even as Biogen dominates biopharma headlines with its high-profile Aduhelm launch, the company’s budding biosimilar business has been quietly building up—and now, it has another …

Continue Reading →
Aduhelm

Citing ‘less-than-optimal’ outcomes for Roche’s Evrysdi, Biogen launches high-dose Spinraza trial

While much of the attention on Biogen lately has centred on its launch of controversial Alzheimer’s disease drug Aduhelm, the company is also feeling the …

Continue Reading →
AbbVie

CEOs of AbbVie, BMS, Lilly, GSK and more raise concerns about Washington’s intensifying drug-pricing push

As officials in Washington weigh contentious drug-pricing measures, there’s even more evidence that pharma companies are worried about potential reform. In an open letter to …

Continue Reading →
Alzheimer

‘I don’t like it:’ Biogen’s latest Alzheimer’s ad rouses fresh Aduhelm concerns—and some defense

Maybe you occasionally forget appointments or social events or lose your train of thought in a conversation. Maybe you’re feeling depressed or overwhelmed when making …

Continue Reading →